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Abstract 
 
The prevalence of atrial fibrillation (AF) in β-thalassemia major (β-TM) patients has increased in 
the last few years, reaching up to 33.0%. Several factors may drive this value to even more in the 
next years. We summarized the main challenges in the management and therapy of AF in this 
very specific group of patients. 
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β-Thalassemia major (β-TM) is a hereditary hemoglobin (Hb) disorder caused by reduced 
synthesis of β-globin chain and resulting in a chronic hemolytic anemia that typically requires 
life-long transfusion therapy. If left untreated, this could result in growth retardation, bone 
marrow expansion, extramedullary hematopoiesis, splenomegaly, greater intestinal iron 
absorption, hypercoagulability and higher susceptibility to infections till death occurs [1-3]. 
 
Although traditionally prevalent in the Mediterranean Basin, Middle East, North India, and 
Southeast Asia, migration of those populations to North America and Western Europe has 
rendered β-thalassemia (β-thal) a global health problem. According to the Thalassemia 
International Federation, (Nicosia, Cyprus), about 200,000 people are affected by β-TM and 
registered as receiving regular treatment around the world [4]. The highest carrier frequency is 
reported in Cyprus (14.0%), Sardinia (10.3%) and Southeast Asia [5]. 
 
Thanks to transfusions and iron chelation, the prognosis of β-TM has dramatically improved, and 
recent studies have shown that the 80.0% of patients in countries with modern therapies 
available, survive to over 40 years of age [6,7]. A further improvement of survival for these 
patients is to be expected from an earlier commencement of chelation therapy and, in the near 
future, with the introduction of new drugs such as Luspatercept and genetic therapy. 
 
Despite the improvements in both therapies and follow-up modalities, cardiac complications 
represent the primary cause of mortality and one of the major causes of morbidity in those 
patients [8-10]. The first reason of cardiac damage is iron overload, due mainly to repetitive 
blood transfusions, as well as hemolysis and increased intestinal absorption. The increase of 
plasma iron turnover results in saturation of the iron storage and transport proteins and the 
appearance of a free plasma iron pool. The iron-mediated oxidative stress can damage 
cardiomyocytes causing lipid peroxidation, mitochondrial injury, membrane disruption, and 
contractile dysfunction. Advanced iron overload, along with inflammation and immunogenetic 
factors, leads to cardiac chamber dilation and focal myocardial degeneration and fibrosis. 
Involvement of the conduction system is less severe and inhomogeneous. Sometimes pericardial 
and pulmonary vascular abnormalities are also present [1,9]. 
 
Heart failure usually develops in patients with non optimal chelation therapy and multi-
endocrinopathies. The incidence of iron overload cardiomyopathy ranges from 11.4 to 15.1% in 
β-TM patients [7,8]. Restrictive cardiomyopathy usually occurs first followed by dilatation, in 
accordance with diastolic dysfunction, which normally precedes systolic dysfunction and overt 
heart failure. From the earliest reporting of the cardiovascular complications of thalassemia, 
arrhythmias were noted to feature prominently [11]. Findings in the early stage are usually 
incidental and include bradycardia, repolarization changes, infrequent premature atrial or 
ventricular contractions and first-degree atrioventricular blocks. In the late stage, atrial and 
ventricular tachycardia and second-degree or complete heart block are common findings [8]. 
 
In atrial tachycardia, the prevalence of atrial fibrillation (AF) is high and, due to longer survival 
of thalassemic patients, may increase in the future with important clinical implications. While 
iron-induced cardiomyopathy is slowly progressive and it usually takes several decades to 
manifest, AF can already be present at the earlier stage of isolated myocardial siderosis [8]. The 
prevalence of AF in adult β-TM patients ranges from 10.0 to 33.8% in the literature, also 
depending on the study methods used to detect AF [12-14]. Atrial fibrillation is frequently badly 
tolerated and is a concern for the patients and a clinical problem for the physician. 
 
Furthermore, which is the possible explanation for this higher prevalence of AF in β-TM 
patients? That brings us back to the concept of Coumel’s triangle. According to Coumel, ‘there 
are always three main ingredients required for the production of a clinical arrhythmia: the 
arrhythmogenic substrate, the trigger factor and the modulation factors of which the most 
common is the autonomic nervous system dysfunction’ [15]. All the elements are present in β-
TM patients. The arrhythmogenic substrate is represented by the iron overload and left atrium 
dilatation. 
 
Early pathological examination of hearts affected by iron overload emphasized the patchiness of 
iron overload [11] with variable iron content present also in the conducting tissue. Iron-loaded 
myocytes show abnormal action potentials with decreased overshoot and shortened action 
potential duration. These features are likely to occur in a patchy distribution at a microscopic 
level and may constitute the electrical substrate for arrhythmogenesis [16]. In a prospective 
series of patients undergoing cardiac magnetic resonance (CMR) scans to detect iron-induced 
fibrosis [17], about 14.0% of patients with severe iron overload (i.e. T2* <6 ms) experienced an 
arrhythmia within 1 year from the CMR scan, and most of these arrhythmias were AF (79.6% of 
patients). Nevertheless, arrhythmias may also occur in patients with a normal myocardial T2*. 
Possible explanations include the existence of atrial iron loading separate from the ventricle, the 
persistence of atrial iron loading despite ventricular clearance, myocarditis, and the longstanding 
pro arrhythmic atrial effects of volume loading and high cardiac output caused by chronic 
anemia [18]. 
 
Left atrium dilatation is more frequent in β-TM patients than in healthy controls and it is 
considered an early feature of cardiac remodeling in β-TM [19]. P-wave dispersion is a 
noninvasive indicator of intra-atrial conduction heterogeneity associated with atrial remodeling. 
It is the substrate for re-entry, which is one of the pathophysiological mechanisms of AF. In the 
study by Russo et al. [20], P-wave dispersion (defined as the difference between the maximum 
P-wave duration and the minimum P-wave duration in the same patient) was significantly 
increased in β-TM patients with AF compared to those without and to normal controls, and 
correlate with myocardial iron deposit assessed by CMR-T2* star imaging. This was confirmed 
in a second study by the same group [12] using external continuous loop recording. Based on 
these reports, an abnormal P-wave dispersion ≥35.5 ms and maximum P-wave duration ≥111 ms, 
can predict AF onset in β-TM patients with conserved systolic and diastolic function [12]. 
However, AF itself is only one of multiple factors as seen in patients affected by β-thal 
intermedia (β-TI) who have less cardiac arrhythmia compared to β-TM patients, despite larger 
chamber volumes. The little cardiac iron found in β-TI patients implies a possible critical role of 
the iron toxicity and the vegetative neural impairment [21]. 
 
As regards the trigger factors leading to the occurrence of AF, ventricular extrasystoles, as well 
as infrequent premature atrial or ventricular contractions and first-degree atrioventricular blocks 
are common findings in β-TM patients; furthermore, these patterns are detectable starting from 
very early stages of cardiac iron overload [8]. 
 
The third factor of Coumel’s triangle is modulation factors and, among others, the most 
important is the nervous system. The β-TM patients present with autonomous nervous system 
dysfunction contributing to arrhythmogenesis [14,18]. Patients with β-TM in fact have been 
shown to have a lower heart rate variability (HRV) compared to normal subjects [22-24]. 
Moreover, the decline in HRV precedes the clinical signs of cardiomyopathy. As suggested by 
Yetimakman et al. [25], in the absence of systolic or diastolic dysfunction, HRV parameters can 
be used to detect early cardiac autonomic involvement, which together with atrial dilatation 
creates a substrate that favors the development of arrhythmias, especially AF. Despite the small 
number of patients included in all the studies we quoted, they all seem to come to the same 
conclusion. 
 
The absence of studies involving large populations with the disease is a limiting factor for a 
better understanding of the pathology and its consequences. There is, for example, a wide range 
in the published literature regarding the prevalence of AF in β-TM patients. 
 
In the first studies, its prevalence was around 10.0% [7,8] but that has reached up to 33.8% in 
recent times [11,13,26]. This increase should alarm β-TM specialists. Atrial fibrillation, in fact, 
is associated with morbidity and increased risk of mortality; stroke is a frequent complication of 
AF, and its risk is associated with several clinical factors summarized by the CHA2DS2-VASc 
scoring system [27]. The growing age of thalassemic population likely contributes to the 
increasing prevalence of AF and, considering the longer survival due to modern treatments, the 
occurrence will probably increase further in the near future. A potential epidemic of AF could 
involve the β-TM population and, considering its potential detrimental damages, physicists 
should be aware of how to face it. Effective treatment starts with early recognition and active 
screening should be suggested to patients, even when cardiac function still appears normal, as 
shown in a recent long-term prospective observational study [28] that revealed an overall AF 
prevalence of 20.9% in a large β-TM-population with a normal cardiac function undergoing 
long-period, external loop recorder (ELR) monitoring every 6 months during their 5-year follow-
up. We summarize below what appears a reasonable outline for the management of the 
antiarrhythmic and anticoagulant therapy in this very specific group of patients. 
 
1) Rate control vs. rhythm control: as patients with β-TM are usually quite young even when 
developing AF, which is the biggest clinical difference in respect to normal AF management, 
rhythm control should always be pursued as long as it is possible. Due to the fact that AF tends 
to be highly symptomatic in these anemic young patients, who often already have a hyper-
dynamic circulatory setting, rate control is often necessary. Due to the lack of evidence in the 
field, both β-blockers and calcium antagonist (diltiazem, verapamil) may be suggested in the 
presence of normal ejection fraction. Caution is needed in patients whose echo shows early tissue 
Doppler abnormalities or who have a history of previous heart failure; in these patients, low 
doses titration is advised. In patients with low T2* values or impaired ejection fraction, digoxin 
might instead be used. 
 
In an acute iron overload state or every time the iron plasmatic level is not adequately controlled, 
the mainstay of the AF treatment as well as of the whole spectrum of thalassemic 
cardiomyopathy is chelation therapy. This means that after an initial period of some months for 
rate control, AF management could be switched to rhythm control. This should be addressed 
especially because the thrombotic risk is less predictable in such patients, on one hand, because 
of the different age scale (with unknown threshold for risk that are surely different from the score 
of a patient who is 64 years old) and on the other hand, because the same thalassemic patients 
who could have a higher intrinsic thrombotic risk when in AF, would be easily managed in 
rhythm because of thrombotic score usually lower than the bleeding scores. 
 
2) Antiarrhythmic therapy. Chelation therapy is the mainstay of arrhythmia management and 
iron overload has to be managed before the administration of any antiarrhythmic drugs. Very few 
studies have evaluated the use of antiarrhythmic drugs for controlling AF in thalassemic patients. 
Regional guidelines as well as panels of international experts suggest that the treatment should 
not differ from the general population [18,29,30]. Considering that non negative-inotrope drugs 
should be preferred. Furthermore, between different antiarrhythmic drugs, those with frequent 
pro arrhythmic effects should be avoided [29], keeping in mind the possible drugs’ interactions 
in these multiple pathologic patients. Finally, the frequent compresence of iron-induced 
endocrine disease, potentially causing arrhythmia or modifying the effect of specific drugs, must 
be considered when choosing the antiarrhythmic therapy [18,31]. Amiodarone is often successful 
in controlling atrial arrhythmias and can be a powerful temporizing measure during intensive 
iron chelation. Long-term therapy may be complicated by hypothyroidism because of the 
frequent association with iron-mediated thyroid injury. However, amiodarone therapy can often 
be successfully terminated after 6 to 12 months, as soon as successful chelation is obtained [18]. 
 
3) Anticoagulant therapy. Atrial fibrillation in β-TM is associated with an increased risk for 
stroke that may be exacerbated by asplenia [32,33]. Anticoagulation is generally recommended 
when heart failure or a history of stroke coexists but a careful risk/benefit ratio assessment 
should be undertaken before anticoagulation is started [34]. Liver function, platelet count, and 
renal function assessments may help establish the bleeding risk and should integrate the well-
known CHADSVASc and HASBLED scores [35]. Due to the documented prothrombotic 
tendencies, permanent anticoagulation has to be considered at an early stage in all patients with 
the only exception of the mildly affected group, who experience infrequent, short-lasting bouts 
of AF [18]. Warfarin is the most used anticoagulant. Only one study explored the effectiveness 
of the new oral anticoagulant rivaroxaban in a small group of patients with β-TM and AF, and 
none of the patients experienced any thrombotic or bleeding event during follow-up [36]. Again, 
drug interactions should be carefully taken into consideration. 
 
4) Catheter ablation therapy. For those patients who cannot tolerate antiarrhythmic drugs and 
those whose AF is poorly controlled, despite the use of such medication, catheter ablation (CA) 
should be considered. It has been shown to be a safe and effective alternative to antiarrhythmia 
in both paroxysmal and persistent AF [37-39]. Current AF guidelines recommend ablation for 
patients with symptomatic AF, who have failed an antiarrhythmic drug therapy based on 
evidence (class I), but acknowledge that ablation may be used in some patients before a trial of 
antiarrhythmic drugs (class IIa) [35]. Catheter ablation indications for β-TM do not differ from 
those for the general population, but as experts suggest it should be reserved for patients who 
have undergone successful removal of cardiac iron documented with CMR [18]. Considering the 
increasing prevalence of AF in β-TM patients and the challenges with antiarrhythmic 
pharmacological therapy, CA is expected to have a greater role in the future. Currently, success 
rates for AF ablation in non thalassemic patients are quoted as being between 70.0 and 80.0% for 
the eradication of the arrhythmia, albeit with a 10.0 to 15.0% likelihood of requiring more than 
one procedures [40]. There are no studies at the moment evaluating the success rate of catheter 
ablation on β-TM patients. Our experience, as well as discussion with experts at other centers, 
seems to agree that even young patients with thalassemia and previous history of iron overload, 
would have a higher level of electrical remodeling with patchy distribution of low voltages zones 
and diffused fragmented potentials that pave the way to complex atypical flutter. The 
pathophysiology of supraventricular tachycardia and AF in the β-TM population may, in fact, be 
different, so that equivalent success rates should not be assumed to apply to this special group of 
patients. Given the already compromised substrate, with almost always dilated atria and the 
effect of exposure of myocardial atrial cells to iron toxicity, it is sometimes more than a feeling 
that such patients should be referred early to CA to make the most of this therapeutic 
opportunity. 
 
Conclusions 
 
The aging of the β-TM population, mostly due to improved chelation therapy, is leading to 
morbidities that are new to this group of patients or used to be less frequent in this specific 
group, such as AF. Atrial fibrillation is a growing problem for β-TM patients. Iron chelation is 
the first and essential therapeutic strategy; as regards more specific therapeutic options including 
antiarrhythmic treatment, anticoagulant therapy, and CA, β-TM patients’ management does not 
differ from the general population. Nevertheless, little is known about the specificity of β-TM 
iron overload-induced cardiomyopathy and its potential specific therapeutic implication. Careful 
selection of patients with higher risk of developing AF to address to cardiac monitoring is 
mandatory in order to early detect its onset and to evaluate the opportunity of prophylactic 
anticoagulation treatment and rhythm management strategies. Based on the published literature 
in the field, we propose an active screening of all thalassemic patients including personal history 
of iron cardiac overload, thyroid disease and symptoms such as palpitation or effort dyspnea and 
regular check of 12-lead electrocardiograms (ECGs), 24-Holter ECG and echocardiographic 
characteristics that have been related to the onset of AF. If a patient has a high number of these 
risk factors, intensive follow-up with external or internal loop recorder might be considered. 
Once an AF diagnosis has been made, a concern due to anticoagulation therapy as the intrinsic 
higher thrombotic risk of this disease should be considered when calculating risk scores that have 
been extrapolated from non thalassemic populations. Rate control strategies should be pursued 
taking into account the potential for heart failure, while rhythm control strategies should rely first 
on optimal iron chelation, short periods of antiarrhythmic drugs and early referral to ablation 
procedure to avoid complex electrical remodeling of the atria. 
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